UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.00 0.00 (0.00%) GOLD FUTURES
2,313.00 +2.00 (+0.09%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,361.64 +1,773.27 (+3.89%)
Mereo BioPharma Group plc (0A9G.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:28PM BST
| Previous close | 3.1500 |
| Open | 3.1600 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.1550 - 3.2700 |
| 52-week range | 0.7059 - 4.3380 |
| Volume | |
| Avg. volume | 8,637 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- GuruFocus.com
Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results
Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024
- Zacks
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
© 2024 Yahoo. All rights reserved.